CN102000134B - Medicine for external use for treating skin inflammation - Google Patents
Medicine for external use for treating skin inflammation Download PDFInfo
- Publication number
- CN102000134B CN102000134B CN 200910172872 CN200910172872A CN102000134B CN 102000134 B CN102000134 B CN 102000134B CN 200910172872 CN200910172872 CN 200910172872 CN 200910172872 A CN200910172872 A CN 200910172872A CN 102000134 B CN102000134 B CN 102000134B
- Authority
- CN
- China
- Prior art keywords
- liquid
- medicine
- pure water
- days
- external use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicine for external use for treating skin inflammation, which comprises the following components by weight percent: an ethanol leachate (liquid A) consisting of honeysuckle, mother chrysanthemum, pure water and Twain 80, an ethanol solution (liquid B) consisting of dyclonine hydrochloride, retinoic acid, laurocapram, alkylpheol ethoxylate and ethanol and an aqueous solution (liquid C) consisting of cannitracin, neomycin, vitamin B6, glycerol and pure water, and the liquid A, the liquid B and the liquid C are uniformly mixed in sequence. The medicine for external use for treating skin inflammation has stronger effect on kill gram negative and positive bacteria, tubercle bacillus, colibacillus, staphylococcus aureus, carbon Da coli, proteus, candidiasis, sporothrix, cryptococcus gattii, aspergillus and the like. The medicine for external use for treating skin inflammation is antibacterial and anti-inflammatory, has the effect of removing pain and relieving itching and has obvious efficacy on skin diseases, such as, skin seborrheic folliculitis, prurigo, acne, haemorrhoids, bedsore, ulcer, eczema, burn, empyrosis, bruise, insect bites and the like.
Description
The present invention relates to a kind of external used medicine of anti-scytitis.The external used medicine constituent of this anti-scytitis, percentage by weight: the alcohol leaching liquid (A liquid) that is formed by Flos Lonicerae, Flos Chrysanthemi Indici, pure water, Tween 80, dehydrated alcohol; The alcoholic solution (B liquid) that is formed by dyclonine hydrochloride, retinoic acid, laurocapram, alkylphenol-polyethenoxy, dehydrated alcohol; The aqueous solution (C liquid) that is formed by cannitracin, neomycin, vitamin B6, glycerol, pure water.In order A liquid, B liquid, C liquid mixing are synthesized.To gram-negative bacteria, positive bacteria, tubercule bacillus, escherichia coli, staphylococcus aureus, charcoal subcutaneous ulcer bacillus, Bacillus proteus, read coccus, sporothrix, cryptococcus, aspergillosis etc., stronger killing action is arranged.Have anti-inflammation, the antipruritic effect of the pain of dispelling.Curative effect to skin diseases such as scytitis, folliculitis, prurigo, acne, hemorrhoid, decubital ulcer, ulcer, eczema, burn, scald, scratch, insect bite wounds is obvious.
The known medicine that is used for the treatment of scytitis has hundreds of, and its function singleness, effect are very little, slow curative effect, and dosage is large and medical expenses are high.And complex manufacturing, equipment investment is large, and production cost is high.
The objective of the invention is in order to solve the defective of above-mentioned existence.A kind of external used medicine of anti-scytitis is provided, now with below external used medicine constituent of this anti-scytitis and preparation method thereof narration:
1, the external used medicine of this anti-scytitis, the constituent of alcohol leaching liquid wherein (A liquid), percentage by weight: formed by Flos Lonicerae 5-10%, Flos Chrysanthemi Indici 5-10%, pure water 10-20%, Tween 80 0.3-0.5%, dehydrated alcohol 40-80%.
2, the external used medicine of this anti-scytitis, the constituent of alcoholic solution wherein (B liquid), percentage by weight: formed by dyclonine hydrochloride 7.5-10%, retinoic acid 0.4-0.5%, laurocapram 7.5-10%, alkylphenol-polyethenoxy 50-70%, dehydrated alcohol 20-25%.
3, the external used medicine of this anti-scytitis, the constituent of pure water solution wherein (C liquid), percentage by weight: formed by cannitracin 0.15-0.3%, neomycin 0.7-1%, vitamin B6 0.3-0.5%, glycerol 3.5-5%, pure water 93.2-95.2%.
4, the external used medicine of this anti-scytitis, its constituent; Percentage by weight: formed by A liquid 20-30%, B liquid 5-10%, C liquid 60-75%.
The external used medicine preparation method of this anti-scytitis, below existing narration:
1, the component Flos Lonicerae and the Flos Chrysanthemi Indici that take in A liquid grind rough segmentation, add mixing and stirring among pure water, add again Tween 80 to continue to stir, under the condition of 35 ℃ after catalytic reaction 24h, add dehydrated alcohol, stir, flooded 15 days, stir 15min every 3 days, then separate, filter, get filtrate for later use.
2, take component in B liquid, be sequentially added among dehydrated alcohol, stir each component is dissolved fully, get alcoholic solution, standby.
3, take component in C liquid, be sequentially added among pure water, stir each component is dissolved fully, get pure water solution, standby.
4, take A liquid, B liquid, C liquid, mixing and stirring in order.Be that the 125g bottle is finished product with vial or plastic bottle packing capacity.
The external used medicine of the anti-scytitis that the present invention relates to has anti-inflammation, an antipruritic effect of the pain of dispelling.Curative effect to dermatosis such as scytitis, folliculitis, prurigo, acne, decubital ulcer, hemorrhoid, ulcer, eczema, burn, scald, scratch, insect bites is obvious.
Advantage of the present invention is that raw material is sufficient, and production technology is simple, and equipment investment is few, and production efficiency is high, and production cost is low, and economic benefit, social benefit are remarkable.
The characteristics that the present invention gives prominence to are to provide a kind of easy to use, safe, external used medicine of effectively treating the scytitis disease for the scytitis Disease.The product price is cheap, can be the patient and alleviates the medical expenses burden.Field work and house and the indispensable medicine of travelling.
Embodiment:
1, take Flos Lonicerae 5kg, Flos Chrysanthemi Indici 5kg, it is ground coarse powder add pure water 20kg, after stirring, add Tween 80 to continue to stir, under the condition of 35 ℃ after catalytic reaction 24h, add dehydrated alcohol 75kg, stir, flooded 15 days, stirred 15min every 3 days, then separate, filter, get alcohol leaching liquid (A liquid), standby.
2, take dyclonine hydrochloride 0.5kg, retinoic acid 0.25kg, laurocapram 0.5kg, alkylphenol-polyethenoxy 2.75kg, dehydrated alcohol 6kg.In order each component is added anhydrously without among alcohol, stir each component is dissolved fully, get alcoholic solution (B liquid), standby.
3, take cannitracin 0.1kg, neomycin 0.5kg, vitamin B6 0.2kg, glycerol 2.5kg, pure water 66.7kg.In order each component is added among pure water, stir each component is dissolved fully, get pure water solution (C liquid), standby.
4, take alcohol leaching liquid (A liquid) 20kg, alcoholic solution (B liquid) 10kg, pure water solution (C liquid) 70kg in order with A liquid, B liquid, C liquid mix homogeneously.Be that the 125g bottle is finished product with vial or plastic bottle packing capacity.
Below test, application result are narrated:
1, acute toxicity test in mice
According to the result of trial test, adopt the HornShi method.If 21500,10000,4640, a 2150/kg4 dosage group.Laboratory animal is selected Kunming kind white mice, body weight 18～22 grams, 10 animals of each dosage group, female, hero half and half.Adopt administration by gavage to tested material, the gavage volume is pressed the 0.4mL/10g body weight and is calculated, and observes for two weeks, the nontoxic level in the true border of acute toxicity.
2, repeatedly skin irritation test
Adopt repeatedly skin irritation test method, laboratory animal is first used 5 of healthy adult white rabbit, and body weight is that 2Kg is left and right, tests and family's rabbit back spinal column diamond wool is cut in front 24 hours, and unhairing scope left and right side is 3 * 3 square centimeters.Sample liquid 0.5mL is spread upon on the side skin of back of rabbit, smear every day once, smeared continuously 14 days.Opposite side compares with distilled water.Observe dermoreaction every day, experiment finishes to get smears position skin and carries out histopathologic examination.
Result of the test, whole tested skins are showed no erythema, edema, reach the skin irritation reactions such as desquamation, and repeatedly the skin irritation index integration is zero.Histopathologic examination, epidermis and corium all find no pathological change, therefore the pathologic diagnosis integration is zero.
According to the repeatedly evaluation criterion evaluation of skin irritation test, to the skin nonirritant.
3, skin irritation test
Adopt one time the skin irritation test method.Laboratory animal is selected 6 of healthy adult white rabbit, body weight 2～2.5Kg.Test and family's rabbit back spinal column diamond wool was cut in front 21 hours, be for experiment.Get tested material 0.5mL and drop in 2.5 * 2.5cm
2Four layers of gauze of size are applied ointment or plaster on the side skin of back of rabbit, then cover with one deck cellophane, then use immobilization with adhesive tape.Opposite side compares with distilled water.Applied ointment or plaster 6 hours, 4,24 and 48 hours observation local skins reaction after removing tested material.
Result of the test, after the removal tested material, 4,24 and 48 hours local skins form without erythema and edema.The scoring of skin irritation response strength is 0 minute.
According to skin irritation intensity evaluation standard evaluation, rabbit skin is had no stimulation.
4, eye irritant test
First use 5 of healthy adult rabbit, the sample application drop is entered in the branch hole conjunctival sac of rabbit, 2 of every eyes.Another branch hole drips distilled water and compares.Make immediately an eye passive group close for 10 seconds after eye drip, after eye drip 6,24,48, hour and checked the damage of rabbit eyes conjunctiva, iris and cornea and recovery situation in 4,7 days (latter dye with 2% Fluress, inspection.As a result, be showed no at the appointed time the eye irritant reaction such as rabbit eyes conjunctiva, the hyperemia of rainbow mould, edema and secretions, have no the corneal opacity, acute eye irritation score index is zero.
According to the evaluation criterion evaluation to the eye stimulus intensity, sample application liquid is to the eye nonirritant.
5, on-the-spot skin degerming test
(1), test basis: carry out according to Ministry of Public Health " disinfection technology " 5.8.1.2 natural bacteria on-site disinfection test method.
(2), test material:
1., test solution: sample stock solution
2., PBS solution: 0.3mol/L, pH:7.2～7.4
3., nertralizer: 0.5% sulfo-sulfur sodium+2% lecithin+2% glycine+5% tween 80
4., disinfecting silk or cotton swab
5., culture medium: Nutrient agar
(3), the method for inspection: after the original liquid of sample soaks with cotton swab, evenly be applied in experimenter's right hand and refer to curved surface, after effect 30min, soak in middle dose with cotton swab, then embrocate sampling in tested position, and constantly change the swab wiping surface, each finger double rub 2 times, cut off the hands contact site, cotton swab is put into 5ml nertralizer pipe, rapping 80 times, drawing sample liquid 1.0ml is inoculated in the sterilization plate (parallel two wares), with pouring into agar plate method, put and cultivate 48h in 37 ℃ of incubators, the clump count of counting planar surface.Matched group is except replacing disinfectant solution to embrocate experimenter's left hand with sterile saline, and all the other are identical with test group.
(4), assay:
6, clinical observation
(1), treatment folliculitis 20 examples, each medication 2ml, sooner or later respectively embrocate the affected part 1 time every day.Wherein 17 example recovery from illness in 7 days, successful, 3 example 14 days recoveries from illness.Effective percentage 100%, obvious effective rate 85%.
(2), Acne treatment 30 examples.Medication every day 1ml respectively embrocates the affected part evening every day 1 time.Wherein 22 example recovery from illness in 7 days, successful, 5 example 14 days recoveries from illness, 3 example 30 days recoveries from illness.Effective percentage, obvious effective rate 73.33%.
(3), the treatment 16 Cases of Decubital Ulcer, each medication 3ml, sooner or later respectively embrocate the affected part 1 time every day.Wherein 8 example recovery from illness in 5 days, 5 example 7 days recoveries from illness, 3 example 12 days recoveries from illness.Effective percentage 100%, obvious effective rate 78%.
(4), treatment ulcer 19 examples, each medication 2ml, sooner or later respectively embrocate the affected part 1 time every day.Wherein 12 example recovery from illness in 7 days, 5 example 11 days recoveries from illness, 2 example 14 days recoveries from illness.Effective percentage 100%, obvious effective rate 63.15%.
(5), treatment eczema 12 examples, each medication 2ml, sooner or later respectively embrocate the affected part 1 time every day.Wherein 9 example recovery from illness in 7 days, 3 example 12 days recoveries from illness.Effective percentage 100%, obvious effective rate 75%.
(6), treatment burn and scald 36 examples, every 10cm, each medication 2ml, sooner or later respectively embrocate the affected part 1 time every day.Wherein 29 example recovery from illness in 7 days, 7 routine patient with severe symptoms 14 days recoveries from illness.Effective percentage 100%, obvious effective rate 80.55%.
(7), treatment skin scratch 60 examples, each medication 1-2ml, sooner or later respectively embrocate the affected part 1 time every day.Wherein 52 example recovery from illness in 7 days, 8 example 11 days recoveries from illness.Effective percentage 100%, obvious effective rate 86.66%.
(8), treatment skin Pruritus 16 examples, each medication 1ml, every day is early, middle and late respectively embrocates the affected part 1 time, wherein 10 example recovery from illness in 1 day, 6 examples 2 days recoveries from illness, effective percentage 100%.Obvious effective rate 62.15%.
The above embodiment of the present invention; only that exemplifying of doing clearly is described; and be not restriction to embodiment of the present invention; percentage by weight and preparation method to the constituent in described field; obviously can make on the basis of the above description other multi-form variation; here need not also can't give all embodiments exhaustive, the variation of other form still is among protection scope of the present invention.
Claims (1)
1. the external used medicine of an anti-scytitis, its preparation method is as follows:
1) take Flos Lonicerae 5kg, Flos Chrysanthemi Indici 5kg, it is ground coarse powder add pure water 20kg, after stirring, add Tween 80 to continue to stir, under the condition of 35 ℃ after catalytic reaction 24h, add dehydrated alcohol 75kg, stir, flooded 15 days, stirred 15min every 3 days, then separate, filter, get alcohol leaching liquid and be A liquid, standby;
2) take dyclonine hydrochloride 0.5kg, retinoic acid 0.25kg, laurocapram 0.5kg, alkylphenol-polyethenoxy 2.75kg, dehydrated alcohol 6kg, each component is added among dehydrated alcohol in order, stir each component is dissolved fully, get B liquid, standby;
3) take cannitracin 0.1kg, neomycin 0.5kg, vitamin B6 0.2kg, glycerol 2.5kg, pure water 66.7kg, in order each component is added among pure water, stir each component is dissolved fully, get C liquid, standby;
4) take A liquid 20kg, B liquid 10kg, C liquid 70kg in order with A liquid, B liquid, C liquid mix homogeneously, obtain the external used medicine of anti-scytitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910172872 CN102000134B (en) | 2009-08-31 | 2009-08-31 | Medicine for external use for treating skin inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910172872 CN102000134B (en) | 2009-08-31 | 2009-08-31 | Medicine for external use for treating skin inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102000134A CN102000134A (en) | 2011-04-06 |
| CN102000134B true CN102000134B (en) | 2013-06-05 |
Family
ID=43808002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910172872 Expired - Fee Related CN102000134B (en) | 2009-08-31 | 2009-08-31 | Medicine for external use for treating skin inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102000134B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824477B (en) * | 2012-09-20 | 2014-09-24 | 张爱生 | Traditional Chinese medicine paste for treating dermatosis |
| CN105748486A (en) * | 2016-04-20 | 2016-07-13 | 辛集市远翔环保能源科技有限公司 | Haemorrhoids treatment composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101254156A (en) * | 2007-03-01 | 2008-09-03 | 段亚东 | Cosmetic composition and uses thereof |
-
2009
- 2009-08-31 CN CN 200910172872 patent/CN102000134B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101254156A (en) * | 2007-03-01 | 2008-09-03 | 段亚东 | Cosmetic composition and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| 夏日肌肤的"解渴"方略;张远桃;《东方食疗与保健》;20050731(第7期);19-20 * |
| 张远桃.夏日肌肤的"解渴"方略.《东方食疗与保健》.2005,(第7期),19-20. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102000134A (en) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109078165B (en) | Composition for nursing female private parts and preparation method and application thereof | |
| CN102860923B (en) | Nano-silver antibacterial liquid soap and preparation method thereof | |
| WO2008140200A1 (en) | External compositions for the skin | |
| CN105411960A (en) | Mask with acne inhibition effect and preparation method thereof | |
| WO2012097466A1 (en) | Pharmaceutical composition and device for preventing, treating and curing ulcers on a diabetic foot and other wounds, which includes snail slime from the species cryptophalus aspersus or helix aspersa müller and pharmaceutically acceptable carriers and/or additives | |
| CN104163847A (en) | Housefly larvae active protein peptide preparation method and housefly larvae active protein peptide prepared thereby and purpose of housefly larvae active protein peptide | |
| CN103860821A (en) | Broad-spectrum disinfectant composition | |
| CN102000134B (en) | Medicine for external use for treating skin inflammation | |
| CN104856978A (en) | Chitosan spraying film agent and preparation method thereof | |
| CN105899221A (en) | Dermatological composition based on algae and olive leaf extracts | |
| Kucharzewski et al. | Stan scheller: the forerunner of clinical studies on using propolis for poor and chronic nonhealing wounds | |
| CN108042626B (en) | Composition with cerumen removing and bacteriostatic effects, preparation and application thereof | |
| CN102600195A (en) | Composite transdermal linimentum for pets as well as preparation method and application of composite transdermal linimentum | |
| RU2636530C2 (en) | Pharmaceutical compositions for treatment of wounds and burns | |
| CN102988844A (en) | Gynaecological gel and extraction method thereof | |
| CN104288222A (en) | Nano-medicine for treating dairy cow endometritis and preparation method of nano-medicine | |
| CN102824337B (en) | Compound chlorhexidine acetate gel for treating livestock endometritis, and preparation method thereof | |
| CN111973551A (en) | Mussel mucin antibacterial gel and preparation method thereof | |
| CN110269839A (en) | A kind of application of cannabidiol CBD and its nano-emulsion in nettle rash or/and preparation for treating rhinitis | |
| CN108078868A (en) | A kind of antiallergic composition for skin care item | |
| RU2535141C1 (en) | Gel composition of wide spectrum of biological action | |
| CN104147044B (en) | Composition for treating piglet staphylococcal exudative epidermitis | |
| CN104083406B (en) | A kind of compound disinfectant and preparation method thereof | |
| CN101897693A (en) | Catechin compounds or application of plant extraction containing same and pharmaceutical composition | |
| CN106074995A (en) | A kind of bactericidal composition for treating female sex organs inflammation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130605 Termination date: 20200831 |